XBIT Overview

Investigation into XBiotech: Pomerantz LLP is investigating claims of securities fraud against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis program due to irregularities in trial results, which led to a significant drop in stock price.

Pomerantz LLP's Background: The firm, known for its expertise in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has secured substantial damages for class members over the years.

Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities in a recent clinical trial.

Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the study's findings and implications for future research arose.

Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities and failure to meet primary study endpoints.

Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the integrity of clinical trial data emerged.

Investigation Announcement: The Schall Law Firm is investigating XBiotech Inc. for potential violations of securities laws related to misleading statements and undisclosed information following the pause of its rheumatoid arthritis drug candidate, Natrunix.

Shareholder Rights: Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free consultation regarding their rights and potential participation in the investigation.